Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Calabresi

Showing results (291-300 of 422) with videos related to

Pageof 43
Sort By:
Annals of Clinical and Translational Neurology|November 18, 2021
Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter studyFriedemann Paul, Peter A Calabresi, Frederik Barkhof, et al.
Neurology|May 26, 2022
Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple SclerosisElias S Sotirchos, Eleni S Vasileiou, Angeliki G Filippatou, et al.
Med (New York, N.Y.)|October 24, 2024
Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive diseaseDimitrios C Ladakis, Kimystian L Harrison, Matthew D Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive diseaseDimitrios C Ladakis, Kimystian L Harrison, Matthew D Smith, et al.
Frontiers in Neurology|January 1, 2021
Optical Coherence Tomography and Optical Coherence Tomography Angiography Findings After Optic Neuritis in Multiple SclerosisOlwen C Murphy, Grigorios Kalaitzidis, Eleni Vasileiou, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2023
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS communityAlan J Thompson, Marcello Moccia, Maria Pia Amato, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2020
Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSDAngeliki G Filippatou, Eleni S Vasileiou, Yufan He, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|June 10, 2021
Optic Neuritis-Independent Retinal Atrophy in Neuromyelitis Optica Spectrum DisorderAngeliki G Filippatou, Eleni S Vasileiou, Yufan He, et al.
Frontiers in Molecular Neuroscience|May 23, 2022
Reactive Astrocytes Derived From Human Induced Pluripotent Stem Cells Suppress Oligodendrocyte Precursor Cell DifferentiationMatthew D Smith, Xitiz Chamling, Alexander J Gill, et al.
Pageof 43

Showing results (291-300 of 422) with videos related to

Sort By:
Pageof 43
Annals of Clinical and Translational Neurology|November 18, 2021
Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter studyFriedemann Paul, Peter A Calabresi, Frederik Barkhof, et al.
Neurology|May 26, 2022
Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple SclerosisElias S Sotirchos, Eleni S Vasileiou, Angeliki G Filippatou, et al.
Med (New York, N.Y.)|October 24, 2024
Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive diseaseDimitrios C Ladakis, Kimystian L Harrison, Matthew D Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive diseaseDimitrios C Ladakis, Kimystian L Harrison, Matthew D Smith, et al.
Frontiers in Neurology|January 1, 2021
Optical Coherence Tomography and Optical Coherence Tomography Angiography Findings After Optic Neuritis in Multiple SclerosisOlwen C Murphy, Grigorios Kalaitzidis, Eleni Vasileiou, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2023
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS communityAlan J Thompson, Marcello Moccia, Maria Pia Amato, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2020
Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSDAngeliki G Filippatou, Eleni S Vasileiou, Yufan He, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|June 10, 2021
Optic Neuritis-Independent Retinal Atrophy in Neuromyelitis Optica Spectrum DisorderAngeliki G Filippatou, Eleni S Vasileiou, Yufan He, et al.
Frontiers in Molecular Neuroscience|May 23, 2022
Reactive Astrocytes Derived From Human Induced Pluripotent Stem Cells Suppress Oligodendrocyte Precursor Cell DifferentiationMatthew D Smith, Xitiz Chamling, Alexander J Gill, et al.
Pageof 43